Details of the Drug Reposition

General Information of This Drug (ID: DMK8AQP)

• Drug Name: Sirukumab (DMK8AQP)
• Drug Type: Monoclonal antibody

Information on Drug Reposition of This Drug

3 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Giant cell arteritis	DISSP87T	4A44.2	Phase 3	[1]
Cutaneous lupus erythematosus	DISOIX6L	EB5Z	Phase 3	[2]
Rheumatoid arthritis	DISTSB4J	FA20	Phase 3	[3]

2 Phase 2 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Major depressive disorder	DIS4CL3X	6A70.3	Phase 2	[4]
Coronavirus Disease 2019 (COVID-19)	DISM7GNX	1D6Y	Phase 2	[5]

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] ClinicalTrials.gov (NCT01856309) Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003. U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT01689532) A Study of CNTO 136 (Sirukumab) Administered Subcutaneously in Japanese Patients With Active Rheumatoid Arthritis Unresponsive to Methotrexate or Sulfasalazine. U.S. National Institutes of Health.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] ClinicalTrials.gov (NCT04380961) A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19. U.S. National Institutes of Health.